Recommendations for Follow-up Care of Individuals With an Inherited Predisposition to Cancer: II. BRCA1 and BRCA2
Abstract
OBJECTIVE: To provide recommendations for cancer surveillance and risk reduction for individuals carrying mutations in the BRCA1 or BRCA2 genes. PARTICIPANTS: A task force with expertise in medical genetics, oncology, primary care, gastroenterology, and epidemiology convened by the Cancer Genetics Studies Consortium (CGSC), organized by National Human Genome Research Institute (previously the National Center for Human Genome Research). EVIDENCE: Studies evaluating cancer risk, surveillance, and risk reduction in individuals genetically susceptible to breast and ovarian cancer were identified using MEDLINE (National Library of Medicine) and from bibliographies of articles thus identified. Indexing terms used were "genetics" in combination with "breast cancer," "ovarian cancer," and "screening," or "surveillance" in combination with "cancer family" and "BRCA1" and "BRCA2." For studies evaluating specific interventions, quality of evidence was assessed using criteria of the US Preventive Services Task Force. CONSENSUS PROCESS: The task force developed recommendations through discussions over a 14-month period. CONCLUSIONS: Efficacy of cancer surveillance or other measures to reduce risk in individuals who carry cancer-predisposing mutations is unknown. Based on expert opinion concerning presumptive benefit, early breast cancer and ovarian cancer screening are recommended for individuals with BRCA1 mutations and early breast cancer screening for those with BRCA2 mutations. No rec…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Five women in the BPM group (19%) and 3 in the UPM group (7%) had previously undergone prophylactic oophorectomy; 18 in the COPM group (49%) had.
“Five women in the BPM Group (19%) and 3 in the UPM group (7%) had previously undergone prophylactic oophorectomy (removal of the ovaries to try to prevent ovarian cancer) which is recommended for consideration by BRCA1/2 mutation carriers [Burke 1997]. Eighteen of the women in the COPM group (49%) had had a prophylactic oophorectomy.”
From Support needs and acceptability of psychological and peer consultation: Attitudes of 108 women who had undergone or were considering prophylactic mastectomy (2008) · cites this paper as Burke 1997
Cited by
Sorted by citations
Meijers-Heijboer, H., van Geel, B., van Putten, W. L. J., Henzen-Logmans, S. C., Seynaeve, C., Menke-Pluymers, M. B. E., Bartels, C. C. M., Verhoog, L. C., van den Ouweland, A. M. W., Niermeijer, M. F., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107193450301 · Cited by 973 · see citing works
American Cancer Society Guidelines for Breast Cancer Screening: Update 2003
Smith, R. A., Saslow, D., Andrews Sawyer, K., Burke, W., Costanza, M. E., Evans, W. P., Foster, R. S., Hendrick, E., Eyre, H. J., & Sener, S. (2003) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.53.3.141 · Cited by 770 · see citing works
Self-citationEaston, D. F., Deffenbaugh, A. M., Pruss, D., Frye, C., Wenstrup, R. J., Allen-Brady, K., Tavtigian, S. V., Monteiro, A. N. A., Iversen, E. S., Couch, F. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/521032 · Cited by 455 · see citing works
Friedreich ataxia: the oxidative stress paradox
Seznec, H., Simon, D., Bouton, C., Reutenauer, L., Hertzog, A., Golik, P., Procaccio, V., Patel, M., Drapier, J.-C., Koenig, M., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi042 · Cited by 219 · see citing works
Outcomes of interest in evidence-based evaluations of genetic tests
Botkin, J. R., Teutsch, S. M., Kaye, C. I., Hayes, M., Haddow, J. E., Bradley, L. A., Szegda, K., & Dotson, W. D. (2010) · Genetics in Medicine · doi:10.1097/gim.0b013e3181cdde04 · Cited by 90 · see citing works
Survival and tumor characteristics of German hereditary breast cancer patients
Hamann, U., & Sinn, H.-P. (2000) · Breast Cancer Research and Treatment · doi:10.1023/a:1006350518190 · Cited by 48 · see citing works
Patenaude, A. F., Orozco, S., Li, X., Kaelin, C. M., Gadd, M., Matory, Y., Mayzel, K., Roche, C. A., Smith, B. L., Farkas, W., et al. (2008) · Psycho-Oncology · doi:10.1002/pon.1279 · Cited by 38 · see citing works
Landau, C., Mitnik, I., Cohen-Mansfield, J., Tillinger, E., Friedman, E., & Lev-Ari, S. (2016) · European Journal of Integrative Medicine · doi:10.1016/j.eujim.2016.04.001 · Cited by 11 · see citing works
- Authors
- Burke, W.
- Corresponding author
- Burke, Wylie
- ORCID
- Burke, Wylie
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 1997-03-26
- Volume
- 277
- Issue
- 12
- Pages
- 997
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W4236095073
- Cited by
- 955
- References
- 0
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 3 · 2023: 3 · 2022: 9 · 2021: 11 · 2020: 10 · 2019: 7 · 2018: 8 · 2017: 11 · 2016: 15 · 2015: 11 · 2014: 10 · 2013: 19 · 2012: 15
- FWCI
- 44.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Keywords
- BRCA1, BRCA2, hereditary breast and ovarian cancer, cancer surveillance, cancer risk reduction, breast cancer screening, ovarian cancer screening, prophylactic surgery, cancer susceptibility
- MeSH terms
- Breast Neoplasms, Contraceptives, Oral, Decision Making, Disease Susceptibility, Female, Genetic Counseling, Genetic Markers, Genetic Testing, Heterozygote, Humans, Life Style, Male, Mammography, Mutation, Neoplasm Proteins, Neoplasms, Hormone-Dependent, Ovarian Neoplasms, Ovariectomy, Prostatic Neoplasms, Risk Factors, Transcription Factors, Colorectal Neoplasms, Estrogen Replacement Therapy, Breast Self-Examination, CA-125 Antigen, Ultrasonography, Doppler, Color, Antineoplastic Agents, Hormonal, Genes, BRCA1, BRCA2 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
